Arvinas Reports Initial Human Administration of Experimental PROTAC® Compound ARV-102 for Neurological Disorders Treatment.

On Jan 25, 2024, the 2024 ASCO_GU summarized a phase III trial on first-time bladder cancer patients treated with neoadjuvant intravesical MMC.

Philogen Announces Preliminary Results from Phase III FIBROSARC Study Evaluating Onfekafusp alfa (L19TNF) in Initial Treatment of Advanced or Metastatic Soft Tissue Sarcoma.

Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class.

Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.

2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.

Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.

BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.

EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.

The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.

Genentech announced that the US FDA has approved Xolair (omalizumab) for reducing allergic reactions.

Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties.